

Chart 2


extract of the leaves of *S. cepharantha* was separated by a combination of crystallization, column chromatography, and preparative TLC, to give a new morphinane alkaloid, cephasugine (**1**), together with 14 known alkaloids: four hasubananes, cephamine (**2**),^{3b} aknadinine (**3**),^{3b} aknadilactam (**4**),^{3b} and cephatonine (**5**)^{3b}; four morphinanes, sinomenine (**6**),^{3c} cephamonine (**7**),^{3c} cephamuline (**8**),^{3c} and stephodeline (**9**)⁴; one bisbenzylisoquinoline, cepharanoline (**10**)^{3d}; three benzylisoquinolines, juziphine (**11**),⁵ norjuziphine (**12**),⁶ and (+)-reticuline (**13**)⁷; one aporphine, litseferine (**14**),⁸ and one proaporphine, stepharine (**15**).⁹

Cephasugine (**1**) was obtained as an amorphous powder, and its molecular formula was established as C₁₉H₂₅NO₅ by the high-resolution mass spectrum (HR-MS). The IR spectrum indicated the presence of a hydroxy group (broad absorption at 3400 cm⁻¹). The ¹H-NMR spectrum

(Table 1) showed the signals of one *N*-methyl group (δ_{H} 2.38), two methoxy groups (δ_{H} 3.69, 3.85), and a set of coupled aromatic protons (δ_{H} 6.56, 6.67) and was similar to that of cephacicine (**16**),^{3b} which is a morphinane alkaloid possessing two acetoxy groups on C-6 and C-7, isolated by us from the tubers of this plant, except for the absence of the signals due to two acetyl groups and the upfield shifts of H-6 (δ_{H} 3.96) and H-7 (δ_{H} 4.34) compared with those (δ_{H} 5.24, 5.92) of **16**. The ¹³C-NMR spectrum (Table 1) was also similar to that of **16**, except for the absence of the signals due to two acetyl groups. These results suggested that the structure of **1**, including the relative stereochemistry should be 6,7-diacetylcephacicine, namely, the *N*-methyl derivative of sinococulicine (**17**).¹⁰ This structure was also supported by the results of correlation *via* long-range coupling (COLOC) and nuclear Overhauser effect spectroscopy (NOESY) experiments

Table 1. ^1H - and ^{13}C -NMR Data for **1** and **16**^{3b)}

Position	^1H		^{13}C	
	1	16	1	16
1	6.56 d (8.2)	6.62 d (8.2)	118.33	118.38
2	6.67 d (8.2)	6.72 d (8.2)	108.75	108.81
3			144.99	145.03
4			143.41	143.40
5	2.17 dd (13.1, 12.5) 2.85 dd (13.1, 3.4)	2.35 dd (13.3, 12.8) 2.86 dd (12.8, 3.8)	35.45	32.75
6	3.96 ddd (12.5, 3.4, 3.4)	5.24 ddd (13.3, 3.8, 3.8)	67.33	68.40
7	4.34 d (3.4)	5.92 dd (3.8, 0.9)	65.65	64.37
8			144.76	141.18
9	4.16 d (5.2)	4.15 d (5.2)	51.82	52.06
10	2.80 ddd (17.7, 5.8, 0.9) 3.11 d (17.7)	2.87 ddd (17.7, 5.8, 1.0) 3.14 d (17.7)	29.32	29.92
11			130.64	130.63
12			128.41	128.01
13			38.07	38.12
14			122.68	125.78
15	1.88 ddd (12.2, 3.7, 1.8) 1.96 ddd (12.2, 12.2, 4.6)	1.87 ddd (12.5, 3.1, 1.8) 2.10 ddd (12.5, 12.2, 4.6)	35.54	35.06
16	2.30 ddd (12.2, 12.2, 3.7) 2.52 ddd (12.2, 4.6, 1.8)	2.38 ddd (12.5, 12.2, 3.1) 2.55 ddd (12.5, 4.6, 1.8)	48.19	48.05
N-CH ₃	2.38 s	2.40 s	42.06	42.15
3-OCH ₃	3.85 s	3.87 s	56.22	56.26
8-OCH ₃	3.69 s	3.55 s	56.77	56.98
6-COCH ₃				170.29
6-COCH ₃		2.01 s		21.03
7-COCH ₃				170.64
7-COCH ₃		2.04 s		21.04

Fig. 1. COLOC (A) and NOE (B) Correlations of **1**

(Fig. 1).

The absolute configuration was deduced as 6*S* (α -H), 7*S* (α -H), and 9*S* (β -H), since the optical activity showed the same sign as that of cephacine (**16**) and sinococuline (**17**). Thus, the structure of **1** was determined to be the *N*-methyl derivative of **17**.

The identification of known alkaloids was confirmed by direct comparison with authentic samples or by comparison of the spectroscopic data with the literature values. Among 15 alkaloids from the leaves, cephasugine

(**1**), stephodeline (**9**), norjuziphine (**12**), and litseferine (**14**) were not isolated from the tubers of the same plant.¹¹⁾ Interestingly, bisbenzylisoquinoline alkaloids, the major alkaloidal group of the tubers, formed a minor alkaloidal group in the leaves, since only cepharanoline (**10**) was isolated, and morphinane and hasubanane alkaloids, which were not obtained from the seeds,¹⁾ were the major alkaloidal groups.

Experimental

Melting points were measured on a Yanagimoto hot-stage melting point apparatus without correction. IR spectra were recorded on an FT/IR-5000 (JASCO) spectrometer as KBr pellets. UV spectra were measured on a Ubest-35 (JASCO) spectrometer. NMR spectra were taken on a JNM- α 500 (JEOL) (500 MHz for ^1H and 125 MHz for ^{13}C) spectrometer in CDCl_3 with tetramethylsilane (TMS) as an internal standard. Optical rotations were determined on a DIP-140 (JASCO) spectrometer. MS were taken on a JMS-D300 (JEOL) spectrometer at 30 eV. Column chromatography was performed on Wakogel C-200 (Wako Pure Chemical Industries, Ltd.). Preparative TLC was done on precoated Silica gel 60 F₂₅₄ (0.25 mm thick) plates (Merck).

Plant Material *Stephania cepharantha* HAYATA was cultivated at Yasato-machi, Ibaraki prefecture, Japan and collected in August 1995.

Extraction and Isolation Dried leaves of *S. cepharantha* (1.33 kg) were extracted twice with hot MeOH. The extract was evaporated *in vacuo*, and the residue (300 g) was treated with 5% HCl. The mixture was filtered, and the filtrate was extracted with Et_2O . The aqueous layer was basified with NH_4OH to pH 10 and extracted with Et_2O to yield the alkaloid-containing fraction (2.82 g). This fraction was subjected to silica gel column chromatography using CHCl_3 , 2%, 4%, and 8% MeOH- CHCl_3 , and MeOH as eluents to afford fractions 1 (0.14 g), 2 (0.44 g), 3 (1.17 g), 4 (0.56 g), and 5 (0.49 g), respectively. Fractions 1–5 were further subjected to a combination of crystallization, column chromatography, and preparative TLC to afford the following alkaloids. From fraction 1; cepharamine (**2**, 45 mg). From fraction 2; aknadinine (**3**, 140 mg), aknadilactam (**4**, 19 mg), cephatonine (**5**, 40 mg), stephodeline (**9**, 4 mg). From fraction 3; aknadinine (**3**, 39 mg), sinomenine (**6**, 67 mg), cephamonine (**7**, 410 mg), cephamuline (**8**, 5 mg), litseferine (**14**, 25 mg), stepharine (**15**, 20 mg). From fraction 4; sinomenine (**6**, 78 mg), cepharanoline (**10**, 67 mg), juziphine (**11**, 32 mg), norjuziphine (**12**, 13 mg), (+)-reticuline (**13**, 47 mg), litseferine (**14**, 15 mg). From fraction 5; cephasugine (**1**, 20 mg).

Cephasugine (1) Amorphous powder. $[\alpha]_D^{25} -98^\circ$ ($c=0.30$, CHCl_3). IR: 3400, 1678, 1605, 1487, 1439, 1282, 1220, 1143 cm^{-1} . UV (MeOH) λ_{max} nm (log ϵ): 283 (3.22). EI-MS m/z (%): 347 (M^+ , 15), 333 (20), 332 (93), 330 (16), 273 (27), 272 (100), 258 (40), 256 (13), 242 (10), 230 (17), 214 (11). HR-MS m/z : 347.1720 ($\text{C}_{19}\text{H}_{25}\text{NO}_5$ requires 347.1730).

Acknowledgments We are grateful to Dr. K. Takeya, Dr. Y. Hitotsuyanagi (Tokyo University of Pharmacy and Life Science) and Dr. M. Akasu (Kaken Shoyaku Co., Ltd.) for valuable information; Mr. Y. Takase (Showa College of Pharmaceutical Sciences) for the MS measurements, and Mr. Y. Mochizuki (Kaken Shoyaku Co., Ltd.) for the cultivation and harvest of *S. cepharantha*.

References

- 1) Kunitomo J., Oshikata M., Akasu M., *Yakugaku Zasshi*, **101**, 951–955 (1981).
- 2) Deng J.-Z., Zhao S.-X., Miao Z.-C., *Phytochemistry*, **31**, 1448–1450 (1992).
- 3) a) Kashiwaba N., Morooka S., Kimura M., Ono M., Toda J., Suzuki H., Sano T., *J. Nat. Prod.*, **59**, 803–805 (1996); b) *Idem*, *ibid.*, **59**, 476–480 (1996); c) Kashiwaba N., Morooka S., Kimura M., Murakoshi Y., Toda J., Sano T., *Chem. Pharm. Bull.*, **42**, 2452–2454 (1994); d) Tomita M., Sawada T., Kozuka M., Takeuchi M., Akasu M., *Yakugaku Zasshi*, **89**, 1678–1681 (1969).
- 4) Charles B., Guinaudeau H., Bruneton J., *Can. J. Chem.*, **67**, 1257–1260 (1989).
- 5) Ziyayev R., Irgashev T., Israilov I. A., Abdullaev N. D., Yunusov M. S., Yunusov S. Y., *Khim. Prir. Soedin.*, **1977**, 239–243.
- 6) Hao H., Qicheng F., *Planta Med.*, **52**, 193–198 (1986).

- 7) Chou C.-J., Lin L.-C., Chen K.-T., Chen C.-F., *J. Nat. Prod.*, **57**, 689—694 (1994).
- 8) Sivakumaran M., Gopinath K. W., *Indian J. Chem., Sect. B*, **14(B)**, 150—151 (1976).
- 9) Bartley J. P., Baker L. T., Carvalho C. F., *Phytochemistry*, **36**, 1327—1331 (1994).
- 10) Itokawa H., Tsuruoka S., Takeya K., Mori N., Sonobe T., Kosemura S., Hamanaka T., *Chem. Pharm. Bull.*, **35**, 1660—1662 (1987).
- 11) Kashiwaba N., Morooka S., Kimura M., Murakoshi Y., Ono M., Toda J., Suzuki H., Sano T., *Chem. Pharm. Bull.*, **45**, 470—475 (1997).